4//SEC Filing
Mahadevia Ankit 4
Accession 0000899243-20-030490
CIK 0001701108other
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 7:00 PM ET
Size
15.9 KB
Accession
0000899243-20-030490
Insider Transaction Report
Form 4
Mahadevia Ankit
Director
Transactions
- Sale
Common Stock
2020-11-03$14.27/sh−2,137$30,490→ 65,817 total - Sale
Common Stock
2020-11-04$14.43/sh−7,370$106,335→ 65,817 total - Exercise/Conversion
Common Stock
2020-11-04$5.90/sh+7,370$43,483→ 73,187 total - Exercise/Conversion
Common Stock
2020-11-03$5.90/sh+2,137$12,608→ 67,954 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-03−2,137→ 502,179 totalExercise: $5.90Exp: 2027-07-05→ Common Stock (2,137 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-04−7,370→ 494,809 totalExercise: $5.90Exp: 2027-07-05→ Common Stock (7,370 underlying)
Footnotes (5)
- [F1]All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507 shares).
- [F2]Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
- [F3]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.35 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.63 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F5]All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001720974
Filing Metadata
- Form type
- 4
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 7:00 PM ET
- Size
- 15.9 KB